DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lpg6tx/bile_duct_cancer) has announced the addition of the "Global Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2013" report to their offering.
'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma).
Scope
- A snapshot of the global therapeutic scenario for Bile Duct Cancer (Cholangiocarcinoma).
- A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of route of administration and molecule type.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Key Topics Covered:
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Bile Duct Cancer (Cholangiocarcinoma) Overview
Therapeutics Development
Companies Involved in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Development
Drug Profiles
- vandetanib
- AP-5346
- Im-0
- triphendiol
- SPI-1620
- elpamotide
- exatecan mesylate
- WT-1 Peptide Vaccine + [gemcitabine]
- gemcitabine
- curcumin + [gemcitabine hydrochloride]
- NUC-1031
- JP-1584
- CAP-7.1
Featured News & Press Releases
Appendix
Companies Mentioned
- Access Pharmaceuticals
- AstraZeneca
- CellAct Pharma
- Daiichi Sankyo Company
- Marshall Edwards
- Mebiopharm
- NuCana BioMed
- Novartis
- OncoTherapy Science
- Provecs Medical
- PCI Biotech
- Spectrum Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/lpg6tx/bile_duct_cancer
